



Rexahn Pharmaceuticals, Inc.  
Investor Relations Department  
15245 Shady Grove Road, Suite  
455  
Rockville, MD 20850  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

AMEX: RNN

Last Trade:	1.85
Trade Time:	8:00 PM ET 10/20/17
Change:	-0.04 <span style="color: red;">↓</span> (2.116%)
Day Range	1.80 - 1.90
52-Week Range	1.27 - 7.10
Volume	447,015


Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- [10/13/17  
Rexahn Announces \\$8 Million Registered Direct Offering](#)
- [10/10/17  
Rexahn Pharmaceuticals Receives Positive Opinion from European Medicines Agency for Orphan Drug Designation for RX-3117](#)
- [09/21/17  
Rexahn Pharmaceuticals to Present at the 2017 Disruptive Growth Company Showcase NYC](#)
- [09/11/17  
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)
- [09/10/17  
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology \(ESMO\) Congress](#)

## Financials [\[ View all \]](#)

- [Fourth Quarter Financial Results](#)
- [02/24/17  
Annual Report \(10-K\)](#)
- [02/24/17  
Proxy Statement \(DEF 14A\)](#)
- [08/04/17  
Quarterly Report \(10-Q\)](#)
- [05/03/17  
Quarterly Report \(10-Q\)](#)
- [11/04/16  
Quarterly Report \(10-Q\)](#)